Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 18-25

  Cai, Kathy Q ^b   Wu, Hong ^b   Klein Szanto, Andres J ^b   Xu, Xiang Xi ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Epithelium; HDM2 MDM2; Heterozygous; Ovarian cancer; p21; Pre malignant lesion; Tp53

Indexed keywords

PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER MORPHOLOGY; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRECANCER; PRIORITY JOURNAL;

ALLELES; CELL TRANSFORMATION, NEOPLASTIC; COLORING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, NEOPLASM; FEMALE; HUMANS; MICRODISSECTION; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349198591     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.023     Document Type: Article

References (30)

1. Scully R.E. Pathology of ovarian cancer precursors. J. Cell. Biochem. Suppl. 23 (1995) 208-218
2. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 18 Suppl 2 (2005) S19-S32
3. Seidman J.D., Russell P., and Kurman R.J. Surface epithelial tumors of the ovary. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract (2002), Springer Verlag, New York 791-904
4. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?. Gynecol. Oncol. 72 (1999) 437-442
5. Boyd J. Whence epithelial ovarian carcinoma?. Gynecol. Oncol. 109 (2008) 161-163
6. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211 (2007) 26-35 Erratum in: J Pathol 2007; 213:116
7. Aoki Y., Kawada N., and Tanaka K. Early form of ovarian cancer originating in inclusion cysts. A case report. J. Reprod. Med. 45 (2000) 159-161
8. Werness B.A., Afify A.M., Bielat K.L., Eltabbakh G.H., Piver M.S., and Paterson J.M. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum. Pathol. 30 (1999) 151-157
9. Yang D.H., Smith E.R., Cohen C., Wu H., Patriotis C., Godwin A.K., et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 94 (2002) 2380-2392
10. Puls L.E., Powell D.E., DePriest P.D., Gallion H.H., Hunter J.E., Kryscio R.J., et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol. Oncol. 47 (1992) 53-57
11. Berchuck A., Kohler M.F., Marks J.R., Wiseman R., Boyd J., and Bast Jr. R.C. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. 70 (1994) 246-252
12. Chan W.Y., Cheung K.K., Schorge J.O., Huang L.W., Welch W.R., Bell D.A., et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am. J. Pathol. 156 (2000) 409-417
13. Kohler M.F., Marks J.R., Wiseman R.W., Jacobs I.J., Davidoff A.M., Clarke-Pearson D.L., et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer. Inst. 85 (1993) 1513-1519
14. DiCioccio R.A., Werness B.A., Peng R., Allen H.J., and Piver M.S. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer. Genet. Cytogenet. 105 (1998) 93-102
15. Boyd J., Hamilton T.C., and Berchuck A. Oncogenes and tumor-suppressor genes. In: Hoskins W.J., Perez C.A., and Young R.C. (Eds). Principles and practice of gynecologic oncology. 3rd ed. (2000), Lippincott, Williams and Wilkins, Philadelphia p103-p128
16. Leitao M.M., Soslow R.A., Baergen R.N., Olvera N., Arroyo C., and Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 93 (2004) 301-306
17. Kohler M.F., Kerns B.J., Humphrey P.A., Marks J.R., Bast Jr. R.C., and Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol. 81 (1993) 643-650
18. Momand J., Zambetti G.P., Olson D.C., George D.L., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
19. Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes. Dev. 7 (1993) 1126-1132
20. Raycroft L., Schmidt J.R., Yoas K., Hao M.M., and Lozano G. Analysis ofp53 mutants for transcriptional activity. Mol. Cell. Biol. 11 (1991) 6067-6074
21. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
22. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
23. Zhang H., Xiong Y., and Beach D. Proliferating cell nuclear antigen and p2l are components of multiple cell cycle kinase complexes. Mol. Biol. Cell. 4 (1993) 897-906
24. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
25. Elbendary A.A., Cirisano F.D., Evans Jr. A.C., Davis P.L., Iglehart J.D., Marks J.R., et al. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer. Res. 2 (1996) 1571-1575
26. Drapkin R., Crum C.P., and Hecht J.L. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum. Pathol. 35 (2004) 1014-1021
27. Casey G., Lopez M.E., Ramos J.C., Plummer S.J., Arboleda M.J., Shaughnessy M., et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13 (1996) 1971-1981
28. Kupryjanczyk J., Thor A.D., Beauchamp R., Merritt V., Edgerton S.M., Bell D.A., et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 4961-4965
29. Garzetti G.G., Ciavattini A., Goteri G., De Nictolis M., Stramazzotti D., Lucarini G., et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol. Oncol. 56 (1995) 169-174
30. Yang D.H., Cai K.Q., Roland I.H., Smith E.R., and Xu X.X. Disabled-2 is an epithelial surface positioning gene. J. Biol. Chem. 282 (2007) 13114-13122